파로스아이바이오
Financials
Valuation Metrics
파로스아이바이오's Market Cap is ₩698B. At end of 2025 it was ₩1216B. Ranked #1492 of 2,436 in KR market (top 61%), #856 of 1,649 on KOSDAQ (top 52%), #164 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 69.78B KRW | KR#1,492/2,436 Sec#164/234 |
| Net Income | -9.94B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 27.96B KRW | KR#2,336/2,436 Sec#223/234 |
| Net Assets | 11.87B KRW | KR#2,350/2,436 Sec#223/234 |
| Employees | 32 | KR#2,166/2,436 Sec#199/234 |
| Value | ||
| P/B | 5.88x | KR#2,270/2,436 Sec#189/234 |
| FCF Yield | -11.98% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -83.72% | KR#2,327/2,436 Sec#216/234 |
| ROA | -35.53% | KR#2,329/2,436 Sec#211/234 |
| Financial Health | ||
| Debt Ratio | 235.61% | KR#1,930/2,436 Sec#208/234 |
| Total Debt | 8.15B KRW | KR#1,680/2,436 Sec#157/234 |
| FCF | -8.36B KRW | KR#1,659/2,436 Sec#138/234 |
| Cash | 7.27B KRW | KR#1,844/2,436 Sec#159/234 |
| Current Ratio | 23.69x | KR#22/2,436 Sec#9/234 |
| Performance | ||
| 1Y Return | -6.10% | KR#855/2,436 Sec#64/234 |
| 1M Return | 2.86% | KR#608/2,436 Sec#52/234 |
| From 52W High | -55.53% | KR#1,475/2,436 Sec#125/234 |
| 1Y MDD | -62.91% | KR#1,580/2,436 Sec#127/234 |
| Trading | ||
| Volume | 72,958 shares | KR#1,121/2,436 Sec#108/234 |
| Foreign Own. | 2.61% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -768 KRW | KR—/2,436 Sec—/234 |
| BPS | 917 KRW | KR#2,299/2,436 Sec#208/234 |
Company Info
Pharos iBio, established in 2016 and listed on KOSDAQ in 2023 as a technology growth company, specializes in new drug development. The company operates an AI-based new drug development platform, Chemibus, integrating large-scale compound big data and multi-omics analysis technology. It focuses on innovative new drug development for rare and intractable diseases, particularly in oncology. Its flagship pipeline, PHI-101, has received orphan drug designation, aiming to accelerate development and enhance market competitiveness. Pharos iBio is headquartered in Anseong-si, Gyeonggi-do.